Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback